BTK and B-cell chronic lymphocytic leukemia: The treatment landscape for CLL has faced profound changes with the development and clinical success of targeted therapies in the past years (47, 48), including the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (49).